中枢性性早熟的治疗
Treatment of Central Precocious Puberty.
作者信息
Eugster Erica A
机构信息
Division of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children at Indiana University Health, Indiana University School of Medicine, Indianapolis, Indiana.
出版信息
J Endocr Soc. 2019 Mar 28;3(5):965-972. doi: 10.1210/js.2019-00036. eCollection 2019 May 1.
Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. Recent years have witnessed much growth in the availability of longer-acting and sustained-release forms of GnRHas. Although all available agents appear promising, limited long-term follow-up and/or comparative data are available. In this review, important issues pertaining to the treatment of children with CPP are discussed. In addition to an assessment of the newer extended-release GnRHa formulations, a delineation of factors essential in determining which children should be treated is offered. Outstanding uncertainties in clinical management are highlighted and areas in need of future research identified. Literature searches for this review were performed in PubMed and OVID, with a focus on English-language publications using the terms "central precocious puberty" and "treatment."
促性腺激素释放激素长效类似物（GnRHas）一直是全球中枢性性早熟（CPP）的金标准治疗方法，并且在安全性和有效性方面有着令人羡慕的记录。近年来，长效和缓释形式的GnRHas的可获得性有了很大增长。尽管所有可用药物似乎都很有前景，但长期随访数据和/或比较数据有限。在这篇综述中，讨论了与CPP患儿治疗相关的重要问题。除了对新型缓释GnRHa制剂进行评估外，还阐述了确定哪些儿童应接受治疗的关键因素。突出了临床管理中存在的显著不确定性，并确定了未来需要研究的领域。本综述的文献检索在PubMed和OVID中进行，重点是使用“中枢性性早熟”和“治疗”等术语的英文出版物。
Zotero 插件